DadFinStart your free week
DadFin › Stocks › Healthcare › PRCT

PROCEPT BioRobotics Corporation (PRCT) stock score

Healthcare · Medical Devices · United States

$18.40 ▲ +2.79% today

43.6
Dad Score, out of 100
middling

PROCEPT BioRobotics Corporation (PRCT) is a Medical Devices company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 43.6 out of 100 on the Dad Score, a middling reading that places the business ahead of 44% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #482 of 974. Its strongest axes are growth, liquidity and macro; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Below average
Growth
Above average
Price action
no inputs
Risk
Average
Conviction
Below average
Liquidity
Above average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-14.9×
Dividend yield0.00%
Return on capital-20.8%
Operating margin-32.0%
Revenue growth (YoY)+37.2%
FCF yield-7.8%
Net debt / EBITDA3.00×
Piotroski F-Score3 / 9
52-week change-51.3%
Market cap$983M
Next earningsNov 4, 2026

What subscribers see on PRCT

Start your free weekSubscriber? Open the full research →

Medical Devices peers

StockCompanyDad ScoreBandMarket cap
ABTAbbott Laboratories78.9good$169.8B
MDTMedtronic plc90.4strong$110.5B
SYKStryker Corporation86.0strong$105.6B
BSXBoston Scientific Corporation94.3strong$61.7B
EWEdwards Lifesciences Corporation49.4middling$49.0B
DXCMDexCom, Inc.82.9good$32.2B
GEHCGE HealthCare Technologies Inc.94.5strong$29.2B
PHGKoninklijke Philips N.V.62.3middling$23.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.